AOD 9604 with tesamorelin is a popular fat-loss peptide stack. Learn how they differ, typical research dosing, safety, and what to know before combining.
AOD 9604 with tesamorelin is a research peptide stack that combines two fat-loss compounds: AOD-9604, a modified fragment of human growth hormone, and tesamorelin, a growth hormone-releasing hormone (GHRH) analog. The idea is that AOD-9604 directly stimulates lipolysis while tesamorelin raises natural growth hormone to reduce visceral fat. No human clinical trial has tested this combination, and neither peptide is approved for general weight loss in the United States.
What Is AOD 9604 With Tesamorelin?
AOD-9604 is a synthetic peptide based on the C-terminal region of human growth hormone (amino acids 176–191). Scientists designed it to capture growth hormone’s fat-burning effects without raising blood sugar or triggering growth-promoting activity. Tesamorelin is a stabilized GHRH analog that tells the pituitary gland to release more growth hormone.
When people search for AOD 9604 with tesamorelin, they are usually asking about a stack used in research settings. The goal is to pair direct lipolytic activity with indirect growth hormone stimulation. These are two separate compounds, not a single FDA-approved product.
How Do These Peptides Work?
AOD-9604
AOD-9604 is studied for stimulating lipolysis, the breakdown of stored fat, and inhibiting lipogenesis, the creation of new fat. It does not appear to raise IGF-1 levels or affect blood sugar the way full growth hormone does. Most research has used subcutaneous injections in animal models and a small number of human trials.
Tesamorelin
Tesamorelin binds to GHRH receptors in the pituitary and prompts the release of growth hormone. That rise in growth hormone can reduce visceral adipose tissue, the deep belly fat linked to metabolic problems. The FDA approved tesamorelin in 2010 under the brand name Egrifta for HIV-associated lipodystrophy.
AOD 9604 vs Tesamorelin: Key Differences
The table below summarizes how these two peptides compare. Remember that AOD-9604 is not approved for human use, while tesamorelin has a narrow FDA approval.
| Feature | AOD-9604 | Tesamorelin |
|---|---|---|
| Drug class | Modified hGH fragment (176–191) | GHRH analog |
| FDA status | Not approved for human use | Approved for HIV-associated lipodystrophy (Egrifta) |
| Main mechanism | Directly stimulates lipolysis; inhibits lipogenesis | Stimulates pituitary growth hormone release |
| Effect on IGF-1 | Minimal or none reported | Raises IGF-1 indirectly |
| Route | Subcutaneous injection (research) | Subcutaneous injection |
| Typical research dose | Often sold as 5 mg vials; human trials used about 1 mg/day | 1.4 mg or 2 mg daily in approved labeling |
AOD-9604 is not FDA-approved for human use in the United States. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy under the brand name Egrifta. Those two facts matter more than any stacking theory.
Is Stacking AOD 9604 With Tesamorelin Studied?
No published human trial has combined AOD-9604 with tesamorelin. Researchers have studied each compound separately, but there is no clinical evidence that the stack is safer or more effective than either peptide alone.
Some people in online communities compare aod 9604 vs mots-c or ask about lipo c vs mots c when choosing a fat-loss peptide. Those comparisons are also based on limited human data. Treat all stacking claims as unproven.
Another common question is whether aod-9604 5mg dosage labels reflect a real human dose. They do not. A 5 mg vial is a packaging size, not a recommended amount, and human dosing has not been standardized.
Dosing, Reconstitution, and Storage for Research Use
Peptides like AOD-9604 and tesamorelin are usually supplied as lyophilized powders that must be reconstituted with bacteriostatic water. Researchers often ask where to buy supplies, but you may not find bacteriostatic water walgreens because it is a research chemical, not a typical retail pharmacy item. Choosing the best bac water for peptides matters for accurate mixing and stability.
Storage questions are common. For example, how long is bac water good for in the fridge depends on the manufacturer and whether the vial has been punctured. Reconstituted peptides usually require refrigeration and should be handled according to the supplier’s instructions.
Always use sterile technique. Never share needles or vials. If you are not a trained researcher, do not attempt to inject research peptides.
Safety, Side Effects, and Legal Status
Tesamorelin can cause injection-site reactions, joint pain, swelling, and changes in blood sugar. It also carries a risk of serious allergic reactions and increased IGF-1 levels. AOD-9604 has been studied in small human trials, but its long-term safety is unknown, and it is not approved for any medical use.
Combining the two could theoretically amplify side effects like water retention, joint pain, or blood sugar changes. There is no safety data on the combination. Anyone considering peptide use should consult a licensed healthcare professional first.
Legality varies. In the US, tesamorelin is a prescription drug for a specific condition. AOD-9604 is not approved and is sold only for research purposes. Buying peptides from unregulated sources carries risks of contamination, incorrect dosing, and legal issues.
Bottom Line on AOD 9604 With Tesamorelin
AOD-9604 and tesamorelin are two different fat-loss peptides with different mechanisms. Tesamorelin has a narrow FDA approval for HIV-associated lipodystrophy, while AOD-9604 remains unapproved for human use. There is no human research on combining them, so the stack is experimental at best.
If you are exploring fat-loss peptides, stick to evidence-based information and talk to a healthcare professional. Research chemicals are not supplements, and self-experimentation can be dangerous.
RELATED PEPTIDE TOPICTesa peptideFrequently Asked Questions
Can you stack AOD 9604 with tesamorelin?
There is no published human research on combining AOD-9604 with tesamorelin. Each peptide has been studied separately, but the stack has not been tested for safety or effectiveness. Talk to a healthcare professional before using any research peptide.
Is AOD 9604 or tesamorelin FDA-approved?
Tesamorelin is FDA-approved for HIV-associated lipodystrophy under the brand name Egrifta. AOD-9604 is not FDA-approved for any human use. That means AOD-9604 is sold only as a research chemical.
What is a typical AOD 9604 dosage?
There is no standard human dose for AOD-9604. Research vials are often labeled as 5 mg, but that is a packaging size, not a recommended amount. Human trials have used around 1 mg per day, but no dosing regimen is approved.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.